TACI / BCMA dual binding molecules

JP2025128160APending Publication Date: 2025-09-02KITE PHARMA INC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2025086025
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-02-15
Filing Date
2025-05-23
Publication Date
2025-09-02

Smart Images

  • Figure 2025128160000035
    Figure 2025128160000035
  • Figure 2025128160000036
    Figure 2025128160000036
  • Figure 2025128160000037
    Figure 2025128160000037
Patent Text Reader

Abstract

To provide CARs and TCRs for targeting and killing cancer cells, in particular, cells expressing transmembrane activator and CAML interactor (TACI) and / or B-cell maturation antigen (BCMA), such as multiple myeloma cells.SOLUTION: Provided is an antibody, or an antigen binding fragment thereof, comprising a dual TACI-BCMA binding domain, wherein the dual TACI-BCMA binding domain comprises sequences of three heavy chain complementarity determining regions (HCDRs) of any one of the heavy chain variable regions (HCVRs) selected from a specified group, and sequences of three light chain CDRs (LCDRs) of the light chain variable regions (LCVRs) selected from a specified group.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • BCMA antigen binding proteins

    US20150344583A1

  • Antibodies that bind both BCMA and taci

    WO2002066516A2